EGFR and neoplasm: The Reactome EGFR pathway ssGSEA score, a measure of downstream EGFR pathway activity, was statistically significantly higher in primary tumours with the EGFR amplification (p = 0.033, Wilcoxon rank-sum test), but no statistically significant difference was seen in recurrent tumours with the EGFR amplification (p = 0.87, Wilcoxon rank-sum test; Figure 2e).